Compare Stocks → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ASPCFNASDAQ:IMRNNASDAQ:KMPHOTCMKTS:SEOVF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/AIMRNImmuron$2.30-1.3%$5.04$1.92▼$28.99$13.11M1.485,644 shs3,554 shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsSEOVFSernova$0.22$0.33$0.22▼$0.83$65.93M1.220,815 shs56,250 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IMRNImmuron+2.46%-1.29%-0.87%+28.65%+12.81%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%SEOVFSernova-8.72%-7.86%-34.45%-57.73%-68.29%Who are Nvidia’s Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.”MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASEOVFSernova1.4544 of 5 stars3.03.00.00.02.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPCFAcerus PharmaceuticalsN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/ASEOVFSernova2.00Hold$1.50590.29% UpsideCurrent Analyst RatingsLatest ASPCF, SEOVF, IMRN, and KMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024SEOVFSernovaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$1.50(Data available from 5/22/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07IMRNImmuron$1.22M10.75N/AN/A$2.32 per share0.99KMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00SEOVFSernovaN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/AIMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/ASEOVFSernova-$28.91M-$0.09N/A∞N/AN/A-226.64%-145.26%6/12/2024 (Estimated)Latest ASPCF, SEOVF, IMRN, and KMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q1 2024SEOVFSernovaN/A-$0.02-$0.02-$0.02N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASPCFAcerus PharmaceuticalsN/A0.670.34IMRNImmuronN/A8.527.79KMPHZevra Therapeutics0.1410.1010.10SEOVFSernova0.141.201.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPCFAcerus PharmaceuticalsN/AIMRNImmuron0.12%KMPHZevra Therapeutics19.39%SEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipASPCFAcerus PharmaceuticalsN/AIMRNImmuron7.01%KMPHZevra Therapeutics1.10%SEOVFSernovaN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableSEOVFSernovaN/A303.41 millionN/ANot OptionableASPCF, SEOVF, IMRN, and KMPH HeadlinesRecent News About These CompaniesMay 18, 2024 | americanbankingnews.comSernova (OTCMKTS:SEOVF) Shares Down 3.7% May 1, 2024 | finance.yahoo.comSernova Announces AGM Voting ResultsApril 26, 2024 | marketbeat.comSernova Corp. (OTCMKTS:SEOVF) Short Interest UpdateMarch 11, 2024 | marketwatch.comSernova Names Nicholas Rossettos Interim CFOJanuary 29, 2024 | msn.comSernova reports anticipated 2024 milestonesNovember 27, 2023 | msn.comSernova gets FDA orphan drug, rare pediatric designations for hemophilia ANovember 14, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Tuesday (SVA)October 30, 2023 | finance.yahoo.comSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint CongressSeptember 29, 2023 | finance.yahoo.comSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual MeetingSeptember 7, 2023 | finance.yahoo.comSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch DeviceSeptember 5, 2023 | marketwatch.comSernova Appoints Cynthia Pussinen as Chief ExecutiveSeptember 5, 2023 | seekingalpha.comSernova appoints CEOJune 26, 2023 | massdevice.comSernova reports positive interim data for Cell Pouch SystemJune 26, 2023 | markets.businessinsider.comSernova (SVA) Receives a Buy from H.C. WainwrightJune 22, 2023 | finance.yahoo.comSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific SessionsJune 16, 2023 | cantechletter.comSernova is significantly undervalued, says EchelonJune 16, 2023 | finance.yahoo.comSernova to Participate in Upcoming Truist Securities Cell Therapy SymposiumJune 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Remains a Buy on Sernova (SVA)May 31, 2023 | finance.yahoo.comSernova Announces Executive Alignment and Appoints New Board ChairMay 8, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Monday (SVA)April 28, 2023 | thenewswire.comSernova Corp. Announces Voting Results of the 2023 Annual General Meeting of ShareholdersNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcerus PharmaceuticalsOTCMKTS:ASPCFAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.SernovaOTCMKTS:SEOVFSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.